Table 1.
The clinicopathological characteristics of patients enrolled.
| NCC | TCGA | GSE31210 | GSE8894 | GSE68571 | GSE42127 | GSE4573 | GSE37745 | GSE30219 | GSE50081 | NCC-bulk | NCC-ICIs | NCC-ICIs | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | 14 | 522 | 226 | 138 | 86 | 176 | 130 | 172 | 106 | 170 | 183 | 40 | 22 |
| Cancer Type | LUAD | LUAD | LUAD | LUAD + LUSC | LUAD | LUAD + LUSC | LUAD | LUAD + LUSC | LUAD + LUSC | LUAD + LUSC | LUAD | Lung cancer | LUAD |
| Agea (years) | 58.3 ± 9.0 | 65.4 ± 10.0 | 59.3 ± 7.8 | 60.8 ± 9.5 | 63.8 ± 9.8 | 66.3 ± 9.7 | 67.5 ± 9.8 | 63.8 ± 9.2 | 61.5 ± 11.6 | 68.8 ± 9.4 | 60.5 ± 8.8 | 56.9 ± 9.2 | 55 ± 8.9 |
| Biological and Self-reported Sex | |||||||||||||
| Female | 8 (57%) | 280 (54%) | 121 (54%) | 34 (24%) | 51 (59%) | 83 (47%) | 48 (37%) | 80 (47%) | 20 (19%) | 80 (47%) | 105 (57%) | 10 (25%) | 9 (41%) |
| Male | 6 (43%) | 242 (46%) | 105 (46%) | 104 (75%) | 35 (41%) | 93 (53%) | 82 (63%) | 92 (53%) | 86 (81%) | 90 (53%) | 78 (43%) | 30 (75%) | 13 (59%) |
| TNM Stage | |||||||||||||
| I | 6 (43%) | 279 (53%) | 168 (74%) | – | 67 (78%) | 112 (64%) | 73 (56%) | 110 (64%) | 75 (71%) | 119 (70%) | 79 (43%) | – | – |
| II | 1 (7%) | 124 (24%) | 58 (26%) | – | 32 (18%) | 34 (26%) | 34 (20%) | 18 (17%) | 51 (30%) | 44 (24%) | – | – | |
| III | 6 (43%) | 85 (16%) | – | – | 19 (22%) | 26 (15%) | 23 (18%) | 23 (13%) | 4 (4%) | – | 60 (33%) | 5 (12.5%) | 4 (18%) |
| IV | 1 (7%) | 26 (5%) | – | – | – | 5 (3%) | – | 4 (2%) | 5 (5%) | – | – | 35 (87.5%) | 18 (82%) |
| Smoking | |||||||||||||
| Ever | 2 (14%) | 356 (68%) | 111 (49%) | – | 74 (86%) | – | 120 (92%) | – | – | 23 (18%) | 57 (31%) | 24 (60%) | 9 (41%) |
| Never | 12 (86%) | 166 (32%) | 115 (51%) | – | 9 (10%) | – | 4 (3%) | – | – | 92 (72%) | 126 (69%) | 16 (40%) | 13 (59%) |
| TP53 | |||||||||||||
| MUT | – | 247 (47%) | – | – | – | – | – | – | – | – | – | – | – |
| WT | – | 260 (50%) | – | – | – | – | – | – | – | – | – | – | – |
| EGFR | |||||||||||||
| 70 (13%) | 127 (56%) | – | – | – | – | – | – | – | – | – | – | ||
| WT | 2 (14%) | 437 (84%) | 68 (30%) | – | – | – | – | – | – | – | – | – | – |
| KRAS | |||||||||||||
| MUT | – | 140 (27%) | 20 (9%) | – | 39 (45%) | – | – | – | – | – | – | – | – |
| WT | – | 367 (70%) | 68 (30%) | – | 46 (54%) | – | – | – | – | – | – | – | – |
| ALK | |||||||||||||
| MUT | 1 (7%) | 23 (4%) | – | – | – | – | – | – | – | – | – | – | – |
| WT | 13 (93%) | 484 (93%) | – | – | – | – | – | – | – | – | – | – | – |
| Platform | – | Illumina-Hiseq | Affy.Plus 2 | Affy.Plus 2 | Affy.HuGeneFL | Illu.WG-6 V3 | Affy.U133A | Affy.Plus 2 | Affy.Plus 2 | Affy.Plus 2 | – | – | – |
| Reference | – | TCGA | Okayama et al., 2012 | Lee et al., 2008 | Beer et al., 2002 | Tang et al., 2013 | Raponi et al., 2006 | Botling et al., 2013 | Rousseaux et al., 2013 | Der et al., 2014 | – | – | – |
Abbreviations: LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; TP53, Tumour Protein P53; MUT, mutation; WT, wild type; EGFR, epidermal growth factor receptor; KRAS, kirsten rat sarcoma viral oncogene; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; N/A = Not Applicable; SD, standard deviation.
a
Mean (SD).